| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 75 | 2024 | 424 | 11.670 |
Why?
|
| Informed Consent | 34 | 2024 | 275 | 10.080 |
Why?
|
| Thyroidectomy | 52 | 2024 | 171 | 8.280 |
Why?
|
| Surgeons | 22 | 2024 | 248 | 8.110 |
Why?
|
| Surgical Procedures, Operative | 24 | 2024 | 206 | 7.290 |
Why?
|
| Ethics, Medical | 29 | 2024 | 307 | 6.340 |
Why?
|
| Physician-Patient Relations | 25 | 2024 | 625 | 5.460 |
Why?
|
| General Surgery | 21 | 2024 | 236 | 4.920 |
Why?
|
| Parathyroidectomy | 26 | 2024 | 77 | 4.420 |
Why?
|
| Pneumonia, Viral | 11 | 2020 | 319 | 3.600 |
Why?
|
| Coronavirus Infections | 11 | 2020 | 304 | 3.600 |
Why?
|
| Decision Making | 17 | 2024 | 667 | 3.330 |
Why?
|
| Humans | 271 | 2024 | 89357 | 2.830 |
Why?
|
| Thyroid Nodule | 12 | 2022 | 58 | 2.610 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 10 | 2022 | 17 | 2.600 |
Why?
|
| Surgery Department, Hospital | 5 | 2020 | 44 | 2.450 |
Why?
|
| Carcinoma, Papillary | 18 | 2021 | 159 | 2.390 |
Why?
|
| Ethics, Research | 7 | 2018 | 52 | 2.380 |
Why?
|
| Hyperparathyroidism, Primary | 11 | 2021 | 42 | 2.210 |
Why?
|
| Specialties, Surgical | 7 | 2021 | 66 | 2.020 |
Why?
|
| Clinical Trials as Topic | 8 | 2020 | 1150 | 1.920 |
Why?
|
| Thyroid Diseases | 11 | 2020 | 105 | 1.880 |
Why?
|
| Clinical Decision-Making | 6 | 2024 | 281 | 1.820 |
Why?
|
| Monitoring, Intraoperative | 9 | 2022 | 110 | 1.810 |
Why?
|
| Pandemics | 11 | 2020 | 773 | 1.790 |
Why?
|
| Incidental Findings | 6 | 2016 | 98 | 1.720 |
Why?
|
| Postoperative Complications | 21 | 2020 | 2284 | 1.640 |
Why?
|
| Thyroid Gland | 16 | 2023 | 280 | 1.640 |
Why?
|
| Parathyroid Neoplasms | 10 | 2016 | 57 | 1.590 |
Why?
|
| Patient Selection | 10 | 2020 | 684 | 1.560 |
Why?
|
| Betacoronavirus | 10 | 2020 | 261 | 1.530 |
Why?
|
| Truth Disclosure | 7 | 2015 | 93 | 1.500 |
Why?
|
| Ethics, Clinical | 5 | 2023 | 48 | 1.480 |
Why?
|
| Physicians | 8 | 2024 | 690 | 1.470 |
Why?
|
| Moral Obligations | 4 | 2024 | 53 | 1.460 |
Why?
|
| Operating Rooms | 3 | 2022 | 129 | 1.430 |
Why?
|
| Personal Autonomy | 4 | 2024 | 116 | 1.420 |
Why?
|
| Preoperative Care | 10 | 2023 | 396 | 1.400 |
Why?
|
| Patient Participation | 4 | 2021 | 224 | 1.350 |
Why?
|
| Diffusion of Innovation | 3 | 2021 | 71 | 1.330 |
Why?
|
| Endocrinology | 10 | 2021 | 50 | 1.320 |
Why?
|
| Hyperparathyroidism, Secondary | 5 | 2024 | 69 | 1.300 |
Why?
|
| Quality Improvement | 5 | 2022 | 451 | 1.300 |
Why?
|
| Parathyroid Hormone | 13 | 2024 | 217 | 1.250 |
Why?
|
| Elective Surgical Procedures | 5 | 2020 | 126 | 1.210 |
Why?
|
| Tissue and Organ Procurement | 6 | 2022 | 347 | 1.180 |
Why?
|
| Physician's Role | 6 | 2020 | 177 | 1.180 |
Why?
|
| Robotic Surgical Procedures | 5 | 2020 | 306 | 1.180 |
Why?
|
| Watchful Waiting | 3 | 2017 | 63 | 1.170 |
Why?
|
| Internship and Residency | 5 | 2023 | 1045 | 1.140 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2024 | 475 | 1.130 |
Why?
|
| Vocal Cord Paralysis | 8 | 2021 | 27 | 1.110 |
Why?
|
| Intraoperative Complications | 7 | 2018 | 188 | 1.100 |
Why?
|
| Organ Transplantation | 5 | 2017 | 276 | 1.100 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2024 | 33 | 1.090 |
Why?
|
| Postoperative Care | 5 | 2020 | 231 | 1.090 |
Why?
|
| Adrenal Gland Neoplasms | 7 | 2024 | 81 | 1.050 |
Why?
|
| Terminal Care | 4 | 2024 | 137 | 1.050 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 435 | 1.040 |
Why?
|
| Inventions | 3 | 2016 | 13 | 1.040 |
Why?
|
| Genomics | 3 | 2023 | 762 | 1.020 |
Why?
|
| Biomedical Research | 6 | 2014 | 398 | 1.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 5 | 2019 | 15 | 1.010 |
Why?
|
| Communication | 8 | 2020 | 460 | 1.010 |
Why?
|
| United States | 42 | 2021 | 6989 | 0.990 |
Why?
|
| Adenoma | 9 | 2015 | 246 | 0.990 |
Why?
|
| Advance Directives | 7 | 2013 | 64 | 0.960 |
Why?
|
| Living Donors | 6 | 2013 | 339 | 0.950 |
Why?
|
| Parathyroid Diseases | 3 | 2009 | 9 | 0.940 |
Why?
|
| Risk Assessment | 14 | 2023 | 2303 | 0.940 |
Why?
|
| Hashimoto Disease | 2 | 2023 | 11 | 0.940 |
Why?
|
| Patient Preference | 2 | 2016 | 111 | 0.930 |
Why?
|
| Certification | 1 | 2024 | 61 | 0.920 |
Why?
|
| Radiopharmaceuticals | 5 | 2019 | 193 | 0.910 |
Why?
|
| Adenocarcinoma, Follicular | 7 | 2017 | 54 | 0.910 |
Why?
|
| Medical Errors | 4 | 2016 | 117 | 0.910 |
Why?
|
| Terminology as Topic | 2 | 2015 | 221 | 0.910 |
Why?
|
| Attitude of Health Personnel | 10 | 2020 | 645 | 0.910 |
Why?
|
| Cultural Diversity | 3 | 2021 | 57 | 0.890 |
Why?
|
| Bioethics | 2 | 2023 | 35 | 0.870 |
Why?
|
| Morals | 2 | 2021 | 94 | 0.870 |
Why?
|
| Disclosure | 2 | 2021 | 110 | 0.870 |
Why?
|
| Recurrent Laryngeal Nerve | 6 | 2021 | 11 | 0.860 |
Why?
|
| Ownership | 2 | 2022 | 26 | 0.850 |
Why?
|
| Neck Dissection | 9 | 2024 | 67 | 0.840 |
Why?
|
| Quality of Life | 9 | 2024 | 1668 | 0.830 |
Why?
|
| Parathyroid Glands | 8 | 2024 | 74 | 0.820 |
Why?
|
| Medical Futility | 4 | 2024 | 31 | 0.820 |
Why?
|
| Leadership | 3 | 2021 | 138 | 0.820 |
Why?
|
| Female | 81 | 2024 | 46202 | 0.810 |
Why?
|
| Pheochromocytoma | 4 | 2024 | 49 | 0.790 |
Why?
|
| Anemia | 1 | 2023 | 130 | 0.780 |
Why?
|
| Resuscitation Orders | 1 | 2022 | 65 | 0.780 |
Why?
|
| Health Care Costs | 4 | 2020 | 235 | 0.780 |
Why?
|
| Stakeholder Participation | 1 | 2021 | 22 | 0.770 |
Why?
|
| Conscience | 1 | 2021 | 20 | 0.770 |
Why?
|
| Clinical Competence | 7 | 2024 | 784 | 0.760 |
Why?
|
| Hypocalcemia | 6 | 2024 | 43 | 0.760 |
Why?
|
| Robotics | 2 | 2016 | 269 | 0.760 |
Why?
|
| Tape Recording | 1 | 2021 | 19 | 0.760 |
Why?
|
| Burnout, Professional | 2 | 2022 | 102 | 0.750 |
Why?
|
| Faculty, Medical | 2 | 2020 | 186 | 0.750 |
Why?
|
| Videotape Recording | 1 | 2021 | 48 | 0.750 |
Why?
|
| Pathology | 2 | 2013 | 32 | 0.740 |
Why?
|
| Smartphone | 1 | 2021 | 39 | 0.730 |
Why?
|
| Patient Comfort | 1 | 2020 | 7 | 0.730 |
Why?
|
| Retrospective Studies | 36 | 2024 | 9057 | 0.720 |
Why?
|
| Self Disclosure | 1 | 2020 | 32 | 0.710 |
Why?
|
| Coronavirus | 1 | 2020 | 18 | 0.700 |
Why?
|
| Survivors | 3 | 2016 | 234 | 0.700 |
Why?
|
| Male | 74 | 2024 | 42411 | 0.680 |
Why?
|
| Motivation | 2 | 2021 | 296 | 0.670 |
Why?
|
| Hormone Replacement Therapy | 1 | 2020 | 85 | 0.670 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2017 | 601 | 0.670 |
Why?
|
| Professional-Family Relations | 3 | 2014 | 54 | 0.660 |
Why?
|
| Calcium | 10 | 2024 | 1175 | 0.660 |
Why?
|
| Healthcare Disparities | 3 | 2023 | 420 | 0.650 |
Why?
|
| Sexual Harassment | 1 | 2019 | 9 | 0.650 |
Why?
|
| Biopsy, Fine-Needle | 10 | 2022 | 106 | 0.640 |
Why?
|
| Hypoparathyroidism | 3 | 2024 | 24 | 0.630 |
Why?
|
| Human Experimentation | 4 | 2013 | 39 | 0.620 |
Why?
|
| Sexism | 1 | 2019 | 53 | 0.620 |
Why?
|
| Suicide | 1 | 2020 | 151 | 0.620 |
Why?
|
| Life Support Care | 2 | 2012 | 50 | 0.620 |
Why?
|
| Kidney Failure, Chronic | 2 | 2014 | 414 | 0.610 |
Why?
|
| Physicians, Women | 1 | 2019 | 56 | 0.610 |
Why?
|
| Health Equity | 1 | 2020 | 94 | 0.600 |
Why?
|
| Middle Aged | 53 | 2024 | 25974 | 0.600 |
Why?
|
| Disease Management | 4 | 2017 | 329 | 0.600 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 461 | 0.600 |
Why?
|
| Emergency Treatment | 1 | 2018 | 45 | 0.600 |
Why?
|
| Patient Satisfaction | 2 | 2020 | 461 | 0.590 |
Why?
|
| Counseling | 2 | 2016 | 164 | 0.580 |
Why?
|
| Neoplasms | 7 | 2016 | 3041 | 0.580 |
Why?
|
| Beneficence | 5 | 2024 | 34 | 0.570 |
Why?
|
| Patient Safety | 2 | 2016 | 218 | 0.560 |
Why?
|
| Research Subjects | 3 | 2014 | 73 | 0.550 |
Why?
|
| Cysts | 2 | 2008 | 106 | 0.550 |
Why?
|
| Emergency Medicine | 1 | 2018 | 125 | 0.550 |
Why?
|
| Palliative Care | 6 | 2013 | 264 | 0.550 |
Why?
|
| Adult | 50 | 2024 | 26607 | 0.540 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2024 | 1365 | 0.540 |
Why?
|
| Hypercalcemia | 3 | 2021 | 62 | 0.540 |
Why?
|
| Laryngeal Nerve Injuries | 2 | 2015 | 3 | 0.530 |
Why?
|
| Patient Care | 2 | 2023 | 102 | 0.530 |
Why?
|
| Patient Education as Topic | 3 | 2015 | 360 | 0.520 |
Why?
|
| Genetic Testing | 2 | 2023 | 537 | 0.520 |
Why?
|
| Prognosis | 17 | 2023 | 3783 | 0.520 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 122 | 0.520 |
Why?
|
| Intraoperative Care | 1 | 2016 | 84 | 0.510 |
Why?
|
| Laryngeal Nerves | 1 | 2015 | 3 | 0.500 |
Why?
|
| Conflict of Interest | 4 | 2014 | 68 | 0.500 |
Why?
|
| Lymphatic Metastasis | 12 | 2024 | 502 | 0.500 |
Why?
|
| Carcinoma | 5 | 2018 | 443 | 0.490 |
Why?
|
| Withholding Treatment | 3 | 2013 | 117 | 0.490 |
Why?
|
| Patient Care Planning | 1 | 2015 | 83 | 0.490 |
Why?
|
| Hyperostosis Frontalis Interna | 1 | 2014 | 5 | 0.490 |
Why?
|
| Infection Control | 3 | 2020 | 120 | 0.490 |
Why?
|
| Carcinoma, Lobular | 1 | 2015 | 81 | 0.480 |
Why?
|
| Critical Illness | 2 | 2015 | 306 | 0.480 |
Why?
|
| Interpersonal Relations | 2 | 2015 | 175 | 0.480 |
Why?
|
| Cognition Disorders | 1 | 2016 | 235 | 0.480 |
Why?
|
| Thymectomy | 2 | 2014 | 31 | 0.470 |
Why?
|
| Monitoring, Physiologic | 2 | 2009 | 266 | 0.470 |
Why?
|
| Video-Assisted Surgery | 3 | 2015 | 6 | 0.470 |
Why?
|
| Pancreatic Neoplasms | 6 | 2020 | 669 | 0.470 |
Why?
|
| Guidelines as Topic | 2 | 2013 | 160 | 0.460 |
Why?
|
| Curriculum | 4 | 2023 | 568 | 0.460 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2016 | 109 | 0.460 |
Why?
|
| Minimally Invasive Surgical Procedures | 9 | 2019 | 253 | 0.460 |
Why?
|
| Intestines | 2 | 2009 | 416 | 0.460 |
Why?
|
| Iodine Radioisotopes | 4 | 2021 | 134 | 0.460 |
Why?
|
| Cohort Studies | 10 | 2022 | 2872 | 0.440 |
Why?
|
| Adrenalectomy | 2 | 2024 | 45 | 0.440 |
Why?
|
| Mastectomy | 1 | 2015 | 245 | 0.440 |
Why?
|
| Patient-Centered Care | 2 | 2016 | 207 | 0.430 |
Why?
|
| Graves Disease | 2 | 2013 | 36 | 0.430 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 260 | 0.420 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 2 | 2022 | 15 | 0.420 |
Why?
|
| Larynx | 3 | 2021 | 38 | 0.410 |
Why?
|
| Laparoscopy | 4 | 2011 | 773 | 0.410 |
Why?
|
| Academic Medical Centers | 5 | 2021 | 385 | 0.410 |
Why?
|
| Consensus | 8 | 2023 | 356 | 0.410 |
Why?
|
| Cranial Nerve Injuries | 1 | 2012 | 3 | 0.410 |
Why?
|
| Coercion | 1 | 2012 | 15 | 0.400 |
Why?
|
| Critical Care | 1 | 2015 | 382 | 0.400 |
Why?
|
| Cognition | 1 | 2016 | 580 | 0.400 |
Why?
|
| Social Responsibility | 4 | 2016 | 57 | 0.390 |
Why?
|
| Evidence-Based Medicine | 4 | 2020 | 433 | 0.390 |
Why?
|
| Surgery, Plastic | 1 | 2012 | 42 | 0.390 |
Why?
|
| Intensive Care Units | 1 | 2015 | 396 | 0.390 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2023 | 838 | 0.390 |
Why?
|
| Vascular System Injuries | 1 | 2011 | 30 | 0.390 |
Why?
|
| Axilla | 1 | 2011 | 104 | 0.380 |
Why?
|
| Practice Guidelines as Topic | 7 | 2020 | 1047 | 0.370 |
Why?
|
| Professional Autonomy | 2 | 2015 | 41 | 0.360 |
Why?
|
| Patient Care Team | 3 | 2022 | 284 | 0.360 |
Why?
|
| Medical Oncology | 1 | 2014 | 383 | 0.360 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 3 | 2018 | 12 | 0.360 |
Why?
|
| Proto-Oncogene Proteins B-raf | 5 | 2022 | 146 | 0.360 |
Why?
|
| Confidentiality | 3 | 2021 | 77 | 0.360 |
Why?
|
| Medical Tourism | 1 | 2010 | 5 | 0.350 |
Why?
|
| Malpractice | 1 | 2010 | 57 | 0.350 |
Why?
|
| Placebos | 2 | 2017 | 214 | 0.350 |
Why?
|
| Commerce | 1 | 2010 | 31 | 0.350 |
Why?
|
| Carcinoma, Papillary, Follicular | 2 | 2020 | 14 | 0.340 |
Why?
|
| Aged | 29 | 2024 | 19165 | 0.340 |
Why?
|
| Struma Ovarii | 1 | 2009 | 1 | 0.330 |
Why?
|
| Program Development | 1 | 2010 | 123 | 0.330 |
Why?
|
| Natural Orifice Endoscopic Surgery | 2 | 2020 | 41 | 0.330 |
Why?
|
| Adenocarcinoma | 3 | 2022 | 1194 | 0.330 |
Why?
|
| Incidence | 11 | 2019 | 1595 | 0.320 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2008 | 12 | 0.320 |
Why?
|
| Adenoma, Oxyphilic | 4 | 2021 | 31 | 0.310 |
Why?
|
| Surveys and Questionnaires | 6 | 2022 | 2624 | 0.310 |
Why?
|
| Risk Factors | 14 | 2024 | 5499 | 0.300 |
Why?
|
| Ultrasonography | 7 | 2019 | 712 | 0.290 |
Why?
|
| Multiple Endocrine Neoplasia | 2 | 2006 | 7 | 0.290 |
Why?
|
| Ischemia | 1 | 2009 | 251 | 0.290 |
Why?
|
| Treatment Outcome | 14 | 2021 | 8241 | 0.290 |
Why?
|
| Educational Status | 3 | 2023 | 195 | 0.290 |
Why?
|
| Neurosurgery | 1 | 2009 | 100 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 2024 | 23 | 0.290 |
Why?
|
| Head and Neck Neoplasms | 3 | 2023 | 1063 | 0.290 |
Why?
|
| Vena Cava, Inferior | 1 | 2008 | 145 | 0.280 |
Why?
|
| Capitation Fee | 1 | 2006 | 2 | 0.280 |
Why?
|
| Internationality | 2 | 2021 | 69 | 0.280 |
Why?
|
| Diagnostic Errors | 1 | 2008 | 160 | 0.280 |
Why?
|
| Societies, Medical | 9 | 2020 | 575 | 0.280 |
Why?
|
| Guideline Adherence | 3 | 2018 | 230 | 0.280 |
Why?
|
| Therapies, Investigational | 3 | 2019 | 17 | 0.280 |
Why?
|
| Neoplasm Staging | 9 | 2020 | 2018 | 0.280 |
Why?
|
| Social Behavior | 2 | 2021 | 299 | 0.270 |
Why?
|
| Cancer Survivors | 2 | 2018 | 95 | 0.270 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2006 | 94 | 0.260 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2005 | 6 | 0.260 |
Why?
|
| Stress, Psychological | 3 | 2020 | 322 | 0.260 |
Why?
|
| Neuroendocrine Tumors | 2 | 2020 | 118 | 0.260 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 1109 | 0.260 |
Why?
|
| Thyroiditis | 2 | 2023 | 10 | 0.260 |
Why?
|
| History, 20th Century | 3 | 2014 | 312 | 0.260 |
Why?
|
| Treatment Refusal | 3 | 2020 | 62 | 0.260 |
Why?
|
| Risk | 4 | 2020 | 657 | 0.260 |
Why?
|
| Neoplasm Invasiveness | 5 | 2021 | 576 | 0.250 |
Why?
|
| Multiple Myeloma | 1 | 2009 | 330 | 0.250 |
Why?
|
| Survival Rate | 8 | 2016 | 1901 | 0.250 |
Why?
|
| Professional Misconduct | 2 | 2022 | 25 | 0.250 |
Why?
|
| Rare Diseases | 2 | 2016 | 70 | 0.250 |
Why?
|
| Precision Medicine | 3 | 2022 | 410 | 0.240 |
Why?
|
| Patient Self-Determination Act | 2 | 2008 | 4 | 0.240 |
Why?
|
| History, 19th Century | 3 | 2017 | 56 | 0.240 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 3011 | 0.240 |
Why?
|
| Intestinal Neoplasms | 2 | 2020 | 64 | 0.240 |
Why?
|
| Metanephrine | 1 | 2024 | 6 | 0.240 |
Why?
|
| Organizational Culture | 3 | 2019 | 32 | 0.240 |
Why?
|
| Judgment | 2 | 2018 | 66 | 0.230 |
Why?
|
| History, 21st Century | 3 | 2021 | 181 | 0.230 |
Why?
|
| Education, Medical, Graduate | 2 | 2005 | 393 | 0.230 |
Why?
|
| Follow-Up Studies | 7 | 2024 | 3666 | 0.230 |
Why?
|
| Cochlear Implantation | 1 | 2024 | 33 | 0.230 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2021 | 27 | 0.220 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 30 | 0.220 |
Why?
|
| Lymph Nodes | 5 | 2021 | 548 | 0.220 |
Why?
|
| Personal Protective Equipment | 2 | 2020 | 33 | 0.220 |
Why?
|
| Total Quality Management | 1 | 2003 | 33 | 0.220 |
Why?
|
| Severity of Illness Index | 4 | 2016 | 1840 | 0.220 |
Why?
|
| Disease Progression | 3 | 2017 | 1489 | 0.210 |
Why?
|
| Personnel Selection | 2 | 2018 | 60 | 0.210 |
Why?
|
| Triage | 2 | 2020 | 111 | 0.210 |
Why?
|
| Professionalism | 1 | 2022 | 25 | 0.210 |
Why?
|
| Early Detection of Cancer | 2 | 2017 | 416 | 0.210 |
Why?
|
| Rural Population | 2 | 2022 | 144 | 0.200 |
Why?
|
| Hyperaldosteronism | 2 | 2018 | 12 | 0.200 |
Why?
|
| Erythrocyte Transfusion | 1 | 2023 | 72 | 0.200 |
Why?
|
| Psychotic Disorders | 1 | 2024 | 195 | 0.200 |
Why?
|
| Paternalism | 3 | 2012 | 24 | 0.200 |
Why?
|
| Perioperative Care | 2 | 2014 | 170 | 0.200 |
Why?
|
| Blood Transfusion | 1 | 2023 | 169 | 0.200 |
Why?
|
| Language | 1 | 2023 | 154 | 0.200 |
Why?
|
| Predictive Value of Tests | 6 | 2017 | 1723 | 0.200 |
Why?
|
| Pain Management | 2 | 2021 | 138 | 0.200 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2022 | 75 | 0.200 |
Why?
|
| Head Injuries, Penetrating | 1 | 2022 | 55 | 0.190 |
Why?
|
| Students, Medical | 2 | 2013 | 419 | 0.190 |
Why?
|
| Frailty | 1 | 2023 | 76 | 0.190 |
Why?
|
| Resuscitation | 2 | 2022 | 109 | 0.190 |
Why?
|
| Planning Techniques | 1 | 2020 | 10 | 0.190 |
Why?
|
| Vascular Neoplasms | 1 | 2021 | 21 | 0.190 |
Why?
|
| Philosophy, Medical | 1 | 2001 | 17 | 0.190 |
Why?
|
| Risk Adjustment | 2 | 2018 | 38 | 0.190 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2020 | 142 | 0.190 |
Why?
|
| Episode of Care | 1 | 2020 | 7 | 0.190 |
Why?
|
| Jugular Veins | 1 | 2021 | 74 | 0.180 |
Why?
|
| Specialty Boards | 1 | 2020 | 24 | 0.180 |
Why?
|
| Social Problems | 1 | 2020 | 10 | 0.180 |
Why?
|
| Nuclear Medicine | 1 | 2020 | 12 | 0.180 |
Why?
|
| Endocrine Surgical Procedures | 1 | 2020 | 3 | 0.180 |
Why?
|
| Coordination Complexes | 1 | 2020 | 20 | 0.180 |
Why?
|
| Fee-for-Service Plans | 1 | 2020 | 30 | 0.180 |
Why?
|
| Octreotide | 1 | 2020 | 23 | 0.180 |
Why?
|
| Republic of Korea | 2 | 2021 | 31 | 0.180 |
Why?
|
| Mental Competency | 2 | 2018 | 49 | 0.180 |
Why?
|
| Obesity, Morbid | 2 | 2016 | 233 | 0.180 |
Why?
|
| Accreditation | 1 | 2020 | 62 | 0.180 |
Why?
|
| SEER Program | 6 | 2019 | 197 | 0.180 |
Why?
|
| Epidemics | 1 | 2020 | 34 | 0.180 |
Why?
|
| Neurologic Examination | 2 | 2012 | 120 | 0.180 |
Why?
|
| Operative Time | 1 | 2020 | 143 | 0.180 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2022 | 99 | 0.180 |
Why?
|
| Models, Economic | 1 | 2020 | 62 | 0.170 |
Why?
|
| Markov Chains | 1 | 2020 | 127 | 0.170 |
Why?
|
| Ophthalmology | 1 | 2020 | 43 | 0.170 |
Why?
|
| ras Proteins | 1 | 2020 | 130 | 0.170 |
Why?
|
| Gender Identity | 1 | 2020 | 53 | 0.170 |
Why?
|
| Hospital Costs | 1 | 2020 | 109 | 0.170 |
Why?
|
| Otolaryngology | 1 | 2020 | 55 | 0.170 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 182 | 0.170 |
Why?
|
| Ethics Committees, Research | 2 | 2018 | 33 | 0.170 |
Why?
|
| Medicare | 2 | 2020 | 425 | 0.170 |
Why?
|
| Insurance Coverage | 1 | 2020 | 120 | 0.170 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 58 | 0.170 |
Why?
|
| Renal Dialysis | 2 | 2014 | 335 | 0.170 |
Why?
|
| Case-Control Studies | 6 | 2019 | 1862 | 0.170 |
Why?
|
| Radionuclide Imaging | 3 | 2014 | 221 | 0.170 |
Why?
|
| Health Resources | 1 | 2020 | 81 | 0.170 |
Why?
|
| Product Recalls and Withdrawals | 1 | 2019 | 2 | 0.170 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2020 | 94 | 0.170 |
Why?
|
| Radiology | 1 | 2021 | 201 | 0.160 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2019 | 25 | 0.160 |
Why?
|
| Clinical Chemistry Tests | 1 | 2019 | 11 | 0.160 |
Why?
|
| Four-Dimensional Computed Tomography | 2 | 2019 | 19 | 0.160 |
Why?
|
| Goiter, Substernal | 1 | 2018 | 3 | 0.160 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2019 | 36 | 0.160 |
Why?
|
| Calcium Gluconate | 1 | 2018 | 4 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 114 | 0.160 |
Why?
|
| Hypertension | 2 | 2018 | 745 | 0.160 |
Why?
|
| Interdisciplinary Communication | 2 | 2018 | 131 | 0.160 |
Why?
|
| Immunoassay | 1 | 2019 | 91 | 0.160 |
Why?
|
| Chicago | 5 | 2020 | 1427 | 0.160 |
Why?
|
| False Negative Reactions | 2 | 2018 | 63 | 0.160 |
Why?
|
| Liability, Legal | 2 | 2009 | 32 | 0.160 |
Why?
|
| Hepatic Artery | 1 | 2019 | 84 | 0.160 |
Why?
|
| Racism | 1 | 2020 | 89 | 0.160 |
Why?
|
| Workflow | 1 | 2018 | 80 | 0.160 |
Why?
|
| Child | 9 | 2022 | 7174 | 0.160 |
Why?
|
| Violence | 1 | 2020 | 153 | 0.150 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 758 | 0.150 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 253 | 0.150 |
Why?
|
| Ablation Techniques | 1 | 2018 | 36 | 0.150 |
Why?
|
| Health Personnel | 1 | 2020 | 215 | 0.150 |
Why?
|
| Laryngoplasty | 1 | 2017 | 5 | 0.150 |
Why?
|
| Social Justice | 2 | 2018 | 54 | 0.150 |
Why?
|
| Suction | 2 | 2008 | 37 | 0.150 |
Why?
|
| Calcitriol | 1 | 2018 | 173 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2006 | 2415 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 1597 | 0.150 |
Why?
|
| Computer Simulation | 2 | 2020 | 1097 | 0.150 |
Why?
|
| Medical Overuse | 1 | 2017 | 36 | 0.150 |
Why?
|
| MicroRNAs | 1 | 2022 | 551 | 0.150 |
Why?
|
| Multitasking Behavior | 1 | 2017 | 1 | 0.150 |
Why?
|
| Vesicovaginal Fistula | 1 | 2017 | 12 | 0.150 |
Why?
|
| Reoperation | 2 | 2017 | 599 | 0.150 |
Why?
|
| Social Perception | 1 | 2018 | 95 | 0.140 |
Why?
|
| Stomach Neoplasms | 1 | 2020 | 282 | 0.140 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2021 | 394 | 0.140 |
Why?
|
| Empathy | 2 | 2010 | 151 | 0.140 |
Why?
|
| Global Health | 2 | 2016 | 187 | 0.140 |
Why?
|
| Age Factors | 6 | 2019 | 1870 | 0.140 |
Why?
|
| Abscess | 1 | 1997 | 94 | 0.140 |
Why?
|
| Travel | 1 | 2017 | 71 | 0.140 |
Why?
|
| Electrosurgery | 1 | 2016 | 10 | 0.140 |
Why?
|
| Ultrasonic Surgical Procedures | 1 | 2016 | 5 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 444 | 0.140 |
Why?
|
| Adrenal Glands | 2 | 2009 | 77 | 0.140 |
Why?
|
| Health Care Surveys | 1 | 2017 | 280 | 0.130 |
Why?
|
| Hirschsprung Disease | 1 | 2016 | 12 | 0.130 |
Why?
|
| Contracts | 1 | 2015 | 2 | 0.130 |
Why?
|
| Psychometrics | 1 | 2017 | 330 | 0.130 |
Why?
|
| Awareness | 1 | 2016 | 89 | 0.130 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2017 | 112 | 0.130 |
Why?
|
| Disability Evaluation | 1 | 2016 | 140 | 0.130 |
Why?
|
| Transcriptome | 1 | 2020 | 630 | 0.130 |
Why?
|
| Professional Competence | 1 | 2016 | 69 | 0.130 |
Why?
|
| Lymphadenopathy | 1 | 2015 | 20 | 0.130 |
Why?
|
| Databases, Factual | 3 | 2019 | 856 | 0.130 |
Why?
|
| Third-Party Consent | 1 | 2015 | 24 | 0.130 |
Why?
|
| Gynecology | 1 | 2017 | 129 | 0.130 |
Why?
|
| Gastric Bypass | 1 | 2016 | 110 | 0.130 |
Why?
|
| Biomarkers, Tumor | 3 | 2016 | 1549 | 0.130 |
Why?
|
| Choristoma | 1 | 2015 | 68 | 0.130 |
Why?
|
| Epigenomics | 1 | 2016 | 103 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 1265 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2015 | 157 | 0.120 |
Why?
|
| Hospitals | 1 | 2018 | 299 | 0.120 |
Why?
|
| Hyperparathyroidism | 2 | 2007 | 67 | 0.120 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 51 | 0.120 |
Why?
|
| Spirituality | 1 | 2015 | 87 | 0.120 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 757 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2018 | 2661 | 0.120 |
Why?
|
| Scotland | 1 | 2014 | 5 | 0.120 |
Why?
|
| Creativity | 1 | 2014 | 5 | 0.120 |
Why?
|
| Biological Assay | 1 | 2014 | 79 | 0.120 |
Why?
|
| History, 18th Century | 1 | 2014 | 21 | 0.120 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2016 | 127 | 0.120 |
Why?
|
| Survival Analysis | 3 | 2021 | 1534 | 0.120 |
Why?
|
| Bioethical Issues | 1 | 2014 | 38 | 0.120 |
Why?
|
| Cause of Death | 1 | 2015 | 269 | 0.120 |
Why?
|
| Mass Screening | 1 | 2018 | 636 | 0.110 |
Why?
|
| Health Policy | 3 | 2020 | 185 | 0.110 |
Why?
|
| Comorbidity | 3 | 2024 | 949 | 0.110 |
Why?
|
| Cisplatin | 2 | 2006 | 618 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2017 | 352 | 0.110 |
Why?
|
| Canada | 3 | 2015 | 208 | 0.110 |
Why?
|
| Voice Disorders | 1 | 2013 | 7 | 0.110 |
Why?
|
| Voice Quality | 1 | 2013 | 7 | 0.110 |
Why?
|
| Health Status | 1 | 2015 | 371 | 0.110 |
Why?
|
| Mutation | 5 | 2024 | 4143 | 0.110 |
Why?
|
| Genetic Variation | 1 | 2020 | 1374 | 0.110 |
Why?
|
| Research Design | 1 | 2017 | 599 | 0.110 |
Why?
|
| Family | 1 | 2015 | 325 | 0.110 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 468 | 0.110 |
Why?
|
| Hematoma | 1 | 2013 | 108 | 0.110 |
Why?
|
| Sex Factors | 4 | 2019 | 1066 | 0.100 |
Why?
|
| Attention | 1 | 2016 | 395 | 0.100 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 6811 | 0.100 |
Why?
|
| Length of Stay | 5 | 2018 | 736 | 0.100 |
Why?
|
| Aging | 1 | 2016 | 718 | 0.100 |
Why?
|
| Adolescent | 8 | 2021 | 9263 | 0.100 |
Why?
|
| Time Factors | 6 | 2016 | 5338 | 0.100 |
Why?
|
| Endoscopy | 1 | 2015 | 350 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2014 | 341 | 0.100 |
Why?
|
| Liver | 1 | 2016 | 1208 | 0.100 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2004 | 83 | 0.100 |
Why?
|
| Electromyography | 1 | 2012 | 193 | 0.090 |
Why?
|
| Young Adult | 7 | 2019 | 6312 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2016 | 657 | 0.090 |
Why?
|
| Esophagectomy | 2 | 2004 | 92 | 0.090 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 988 | 0.090 |
Why?
|
| Lymph Node Excision | 3 | 2017 | 220 | 0.090 |
Why?
|
| Liver Failure, Acute | 1 | 2011 | 39 | 0.090 |
Why?
|
| Diagnostic Imaging | 3 | 2021 | 479 | 0.090 |
Why?
|
| Right to Die | 1 | 2010 | 12 | 0.090 |
Why?
|
| Jurisprudence | 1 | 2010 | 25 | 0.090 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 2010 | 6 | 0.090 |
Why?
|
| Biomedical Technology | 1 | 2010 | 21 | 0.090 |
Why?
|
| Capital Punishment | 1 | 2010 | 3 | 0.090 |
Why?
|
| Adenoids | 1 | 2009 | 9 | 0.090 |
Why?
|
| Nuclear Reactors | 1 | 2009 | 7 | 0.090 |
Why?
|
| Craniocerebral Trauma | 1 | 2010 | 56 | 0.090 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2010 | 27 | 0.090 |
Why?
|
| Scalp | 1 | 2010 | 72 | 0.090 |
Why?
|
| Palatine Tonsil | 1 | 2009 | 30 | 0.090 |
Why?
|
| Safety | 1 | 2010 | 149 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2012 | 683 | 0.090 |
Why?
|
| Ethics | 1 | 2009 | 24 | 0.090 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 105 | 0.080 |
Why?
|
| Data Collection | 3 | 2000 | 375 | 0.080 |
Why?
|
| Specialization | 2 | 2008 | 66 | 0.080 |
Why?
|
| Prisoners | 1 | 2010 | 45 | 0.080 |
Why?
|
| China | 1 | 2010 | 233 | 0.080 |
Why?
|
| Laparotomy | 1 | 2009 | 67 | 0.080 |
Why?
|
| Neural Conduction | 1 | 2009 | 71 | 0.080 |
Why?
|
| Medicine | 2 | 2008 | 91 | 0.080 |
Why?
|
| Medical Staff, Hospital | 2 | 2000 | 108 | 0.080 |
Why?
|
| Propensity Score | 2 | 2021 | 147 | 0.080 |
Why?
|
| Infusions, Intravenous | 2 | 2020 | 435 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2010 | 280 | 0.080 |
Why?
|
| Philosophy | 1 | 2008 | 9 | 0.080 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1671 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2024 | 4289 | 0.080 |
Why?
|
| Colectomy | 1 | 2009 | 172 | 0.080 |
Why?
|
| Professional Practice | 1 | 2008 | 46 | 0.070 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2010 | 223 | 0.070 |
Why?
|
| Intraoperative Period | 2 | 2019 | 90 | 0.070 |
Why?
|
| Registries | 3 | 2021 | 784 | 0.070 |
Why?
|
| Pre-Eclampsia | 1 | 2010 | 254 | 0.070 |
Why?
|
| Intestinal Obstruction | 1 | 2007 | 89 | 0.070 |
Why?
|
| Health Services Accessibility | 2 | 2017 | 428 | 0.070 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 40 | 0.070 |
Why?
|
| Biomarkers | 2 | 2018 | 1767 | 0.070 |
Why?
|
| Bariatric Surgery | 1 | 2008 | 196 | 0.070 |
Why?
|
| Neck | 3 | 2015 | 104 | 0.070 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 337 | 0.070 |
Why?
|
| Thiazolidinediones | 1 | 2006 | 73 | 0.070 |
Why?
|
| Virtues | 1 | 2005 | 13 | 0.060 |
Why?
|
| Cetuximab | 1 | 2006 | 117 | 0.060 |
Why?
|
| Government Regulation | 1 | 2005 | 49 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 2340 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2006 | 167 | 0.060 |
Why?
|
| Advisory Committees | 2 | 2018 | 89 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2006 | 301 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2008 | 491 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 1214 | 0.060 |
Why?
|
| Kidney Transplantation | 2 | 2009 | 850 | 0.060 |
Why?
|
| Deoxycytidine | 1 | 2006 | 238 | 0.060 |
Why?
|
| Arizona | 1 | 2004 | 10 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 2015 | 0.060 |
Why?
|
| Histocompatibility Testing | 1 | 2004 | 137 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2018 | 296 | 0.060 |
Why?
|
| Endothelium, Corneal | 2 | 1995 | 19 | 0.060 |
Why?
|
| Gift Giving | 1 | 2004 | 5 | 0.060 |
Why?
|
| Ethical Theory | 1 | 2004 | 10 | 0.060 |
Why?
|
| Logistic Models | 2 | 2019 | 1213 | 0.060 |
Why?
|
| Paclitaxel | 1 | 2006 | 479 | 0.060 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 2 | 1995 | 79 | 0.060 |
Why?
|
| North America | 2 | 2018 | 184 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 1714 | 0.060 |
Why?
|
| Cochlear Implants | 1 | 2024 | 35 | 0.060 |
Why?
|
| Catecholamines | 1 | 2024 | 92 | 0.060 |
Why?
|
| Altruism | 1 | 2004 | 34 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 2011 | 1180 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2006 | 370 | 0.060 |
Why?
|
| Hearing Loss | 1 | 2024 | 59 | 0.050 |
Why?
|
| Indocyanine Green | 1 | 2023 | 22 | 0.050 |
Why?
|
| Transplants | 1 | 2003 | 41 | 0.050 |
Why?
|
| Deception | 1 | 2003 | 20 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2024 | 308 | 0.050 |
Why?
|
| Health Care Rationing | 1 | 2003 | 83 | 0.050 |
Why?
|
| Head | 1 | 2023 | 137 | 0.050 |
Why?
|
| Research Support as Topic | 1 | 2003 | 85 | 0.050 |
Why?
|
| Optical Imaging | 1 | 2023 | 50 | 0.050 |
Why?
|
| Latin America | 1 | 2021 | 13 | 0.050 |
Why?
|
| Research | 1 | 2003 | 252 | 0.050 |
Why?
|
| Thyroglobulin | 1 | 2002 | 59 | 0.050 |
Why?
|
| Adenoma, Islet Cell | 1 | 2001 | 28 | 0.050 |
Why?
|
| Spinal Fusion | 1 | 2002 | 86 | 0.050 |
Why?
|
| Pyridones | 1 | 2022 | 56 | 0.050 |
Why?
|
| Lumbar Vertebrae | 1 | 2002 | 151 | 0.050 |
Why?
|
| Mental Health | 1 | 2003 | 178 | 0.050 |
Why?
|
| Appendicitis | 1 | 2002 | 64 | 0.050 |
Why?
|
| Imidazoles | 1 | 2022 | 148 | 0.050 |
Why?
|
| Carcinoid Tumor | 1 | 2001 | 45 | 0.050 |
Why?
|
| Algorithms | 3 | 2018 | 1877 | 0.050 |
Why?
|
| Ultrasonography, Interventional | 1 | 2021 | 123 | 0.050 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2001 | 35 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 465 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 860 | 0.050 |
Why?
|
| Models, Organizational | 1 | 2001 | 47 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2020 | 18 | 0.050 |
Why?
|
| Patient Advocacy | 1 | 2001 | 52 | 0.050 |
Why?
|
| Suicide, Assisted | 1 | 2001 | 32 | 0.050 |
Why?
|
| Morbidity | 1 | 2001 | 149 | 0.050 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2001 | 112 | 0.050 |
Why?
|
| Reimbursement Mechanisms | 1 | 2020 | 41 | 0.050 |
Why?
|
| Policy Making | 1 | 2020 | 62 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2002 | 261 | 0.040 |
Why?
|
| Hepatectomy | 1 | 2001 | 170 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 58 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2006 | 969 | 0.040 |
Why?
|
| Uncertainty | 1 | 2020 | 74 | 0.040 |
Why?
|
| Neurosurgical Procedures | 1 | 2022 | 232 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 131 | 0.040 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 59 | 0.040 |
Why?
|
| Cholecystitis | 1 | 1999 | 15 | 0.040 |
Why?
|
| Costs and Cost Analysis | 2 | 2013 | 153 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2016 | 773 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 1412 | 0.040 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 3 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2020 | 302 | 0.040 |
Why?
|
| Organometallic Compounds | 1 | 2020 | 134 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2019 | 85 | 0.040 |
Why?
|
| Tracheomalacia | 1 | 2018 | 2 | 0.040 |
Why?
|
| Anesthesia, Endotracheal | 1 | 2018 | 6 | 0.040 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1999 | 56 | 0.040 |
Why?
|
| Medical Audit | 1 | 1999 | 39 | 0.040 |
Why?
|
| Adrenocortical Adenoma | 1 | 1998 | 2 | 0.040 |
Why?
|
| Ethics, Professional | 1 | 2018 | 10 | 0.040 |
Why?
|
| Hypokalemia | 1 | 2018 | 23 | 0.040 |
Why?
|
| Cross Infection | 1 | 2020 | 147 | 0.040 |
Why?
|
| Publication Bias | 1 | 2018 | 13 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2021 | 252 | 0.040 |
Why?
|
| Ethics Consultation | 1 | 2018 | 12 | 0.040 |
Why?
|
| Multidetector Computed Tomography | 1 | 2019 | 59 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2021 | 253 | 0.040 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 1998 | 18 | 0.040 |
Why?
|
| Publications | 1 | 2018 | 27 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2018 | 92 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 895 | 0.040 |
Why?
|
| Pneumothorax | 1 | 2018 | 53 | 0.040 |
Why?
|
| Tracheostomy | 1 | 2018 | 45 | 0.040 |
Why?
|
| Urban Population | 1 | 2019 | 224 | 0.040 |
Why?
|
| Injections | 1 | 2017 | 116 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2016 | 2486 | 0.040 |
Why?
|
| Intubation, Intratracheal | 1 | 2018 | 148 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 2758 | 0.040 |
Why?
|
| Pilot Projects | 1 | 1999 | 871 | 0.030 |
Why?
|
| Organizational Policy | 2 | 2011 | 55 | 0.030 |
Why?
|
| Body Temperature | 1 | 2016 | 125 | 0.030 |
Why?
|
| Tamoxifen | 1 | 1996 | 168 | 0.030 |
Why?
|
| Tissue Donors | 2 | 2013 | 494 | 0.030 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2018 | 216 | 0.030 |
Why?
|
| Pancreatic Polypeptide | 1 | 2015 | 9 | 0.030 |
Why?
|
| Chromogranin A | 1 | 2015 | 8 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 219 | 0.030 |
Why?
|
| CpG Islands | 1 | 2016 | 157 | 0.030 |
Why?
|
| Goals | 1 | 2016 | 67 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 661 | 0.030 |
Why?
|
| Calcitonin | 1 | 2015 | 38 | 0.030 |
Why?
|
| Mannitol | 1 | 1995 | 50 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 66 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3448 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 312 | 0.030 |
Why?
|
| Phenotype | 1 | 2021 | 2440 | 0.030 |
Why?
|
| Finland | 1 | 2014 | 28 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1431 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 106 | 0.030 |
Why?
|
| Swine | 1 | 2016 | 582 | 0.030 |
Why?
|
| Frozen Sections | 1 | 2014 | 49 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 207 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 421 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 225 | 0.030 |
Why?
|
| Glucose | 2 | 1995 | 630 | 0.030 |
Why?
|
| Netherlands | 1 | 2013 | 21 | 0.030 |
Why?
|
| Codes of Ethics | 1 | 2013 | 12 | 0.030 |
Why?
|
| Ca(2+) Mg(2+)-ATPase | 1 | 1993 | 1 | 0.030 |
Why?
|
| Warfare | 1 | 2013 | 10 | 0.030 |
Why?
|
| Investments | 1 | 2013 | 6 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2014 | 590 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2020 | 1525 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2013 | 43 | 0.030 |
Why?
|
| Retirement | 1 | 2013 | 12 | 0.030 |
Why?
|
| Proxy | 1 | 2013 | 26 | 0.030 |
Why?
|
| Disasters | 1 | 2013 | 22 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2010 | 3731 | 0.030 |
Why?
|
| Pregnancy | 2 | 2010 | 3018 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 899 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2013 | 147 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 2012 | 60 | 0.030 |
Why?
|
| Death | 1 | 2013 | 85 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 781 | 0.030 |
Why?
|
| Workload | 1 | 2013 | 129 | 0.020 |
Why?
|
| Financial Support | 1 | 2011 | 7 | 0.020 |
Why?
|
| Fatigue | 1 | 2012 | 179 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 2566 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2012 | 138 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 1144 | 0.020 |
Why?
|
| Prevalence | 1 | 2015 | 1243 | 0.020 |
Why?
|
| DNA | 2 | 1995 | 1308 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1799 | 0.020 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2013 | 179 | 0.020 |
Why?
|
| Pregnancy in Diabetics | 1 | 2010 | 38 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 299 | 0.020 |
Why?
|
| Kidney Calculi | 1 | 2012 | 343 | 0.020 |
Why?
|
| Depression | 1 | 2012 | 505 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2401 | 0.020 |
Why?
|
| Parents | 1 | 2010 | 285 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2009 | 780 | 0.020 |
Why?
|
| Weight Loss | 1 | 2008 | 227 | 0.020 |
Why?
|
| Naphthalenes | 1 | 2006 | 45 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2006 | 60 | 0.020 |
Why?
|
| Culture Media | 2 | 1995 | 147 | 0.010 |
Why?
|
| Cattle | 2 | 1995 | 375 | 0.010 |
Why?
|
| Cadaver | 1 | 2004 | 185 | 0.010 |
Why?
|
| Resource Allocation | 1 | 2004 | 65 | 0.010 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2002 | 22 | 0.010 |
Why?
|
| Animals | 3 | 2016 | 27371 | 0.010 |
Why?
|
| Cell Membrane | 2 | 1995 | 672 | 0.010 |
Why?
|
| Gangrene | 1 | 1999 | 7 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 1995 | 2884 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 1719 | 0.010 |
Why?
|
| Acute Disease | 1 | 1999 | 841 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1995 | 181 | 0.010 |
Why?
|
| Remission Induction | 1 | 1996 | 740 | 0.010 |
Why?
|
| DNA Damage | 1 | 1993 | 371 | 0.010 |
Why?
|
| Infant, Premature | 1 | 1952 | 298 | 0.010 |
Why?
|
| Infant | 1 | 1952 | 3160 | 0.000 |
Why?
|